National Brain Tumor Society’s Post

Without biomarker testing we're not going to create longer-term lung cancer survivors. That's why our Board Member, Summer Farmen spoke at Foundation Medicine yesterday. Summer said, "Without biomarker testing, my treatment plan would be very different and not as effective." She also shared hopes that this field can help create more long-term cancer survivors. #StrongerTogether #ResearchMatters #BiomarkerTesting #BiomarkersMatter #ResearchSavesLives #patientadvocacy #patientvoice

This content is intended for U.S. Healthcare Providers. Antibody-drug conjugates #ADCs are one emerging class of therapy in advanced or metastatic NSCLC. Explore the fundamentals of ADCs as a therapeutic approach with lung cancer experts. Watch the Cancer Conversations now at ADCevolution: https://lnkd.in/dwejCexp Reference: Coleman, N et al. NPJ Precis Oncol.2023;7(1):5.

Lung cancer remains one of the most prevalent forms of Cancer worldwide, often diagnosed at a late stage when treatment options are more limited. This World Lung Cancer Day, by fostering a greater understanding of the disease and supporting efforts to combat it, we at COD aim to advance clinical research and drug development, and to emphasize the importance of early detection. To know more about us, write to us at bd@cod-research.com Designing Therapies for Future #WorldLungCancerDay2024 #WLCD24 #ClosetheCareGap #EveryoneDeservesAccesstoCancerCare #CODResearch

🗓️August is World Lung Cancer Day 🫁 Through the Time to Accelerate: for Cancer Screening campaign ECO is uniting medical societies and patient groups to implement and update national screening strategies across the EU. Read more 🔗 https://lnkd.in/dUAGi_pS Together, we can make a difference! #EUCancerPlan

Excited to share our latest research poster: 'Advancements in Lung Cancer Management: Role of ctDNA in Early Detection, Prognosis, and Personalized Treatment.' Delving into the potential of ctDNA biomarkers to revolutionize lung cancer care with non-invasive diagnostics and tailored therapies. A special thank you to our supervisor, Shezaib Siddiqui , for his invaluable guidance and support throughout the planning and working of this poster. Looking forward for your valuable feedbacks and suggestions! #LungCancerResearch #ctDNA #PersonalizedMedicine #EarlyDetection #CancerBiomarkers

Amoy Diagnostics (SZSE:300685)'s HRD Focus panel, evaluated in Mexican patients with high-grade serous ovarian cancer, demonstrates strong concordance with established assays and identifies additional BRCA variants missed by other tests. Check out the study below, which shows that the panel's HRD positivity rate aligns well with major clinical trials, highlighting its efficacy in guiding targeted therapies. #PrecisionMedicine #OvarianCancer #MedicalInnovation #QimingPortfolio #QimingHealthcare

🌐 #OncologyUpdate: Are you keeping pace with the rapid changes in cancer treatment? Adapting to new data and emerging therapies is crucial to enhancing patient care. Traditional methods like journals and lectures can't keep up. We're thrilled to introduce you to Cancer Expert Now's platform for instant, ongoing updates directly from primary investigators and leading innovators. Stay at the forefront of oncology and enrich your practice by applying the latest data to your patients' unique cases.✨ https://lnkd.in/eFp_9WRd Join the conversation and be part of the evolution of cancer care. #CancerCare #Innovation #ClinicalPractice #PatientOutcomes

📢 Now live: Pathway to Success in Cancer Treatment, Achieving Radioligand Capacity and Readiness. This paper is a summary of highlights from a multi-stakeholder public working session held at The European Parliament On April 11, 2024, and subsequent discussions on IQVIA Institute’s published report, The State of Radioligand Therapy Readiness in Europe. Read what the experts had to say about necessary actions as innovative therapies continue to enter the cancer care paradigm: https://bit.ly/3B0W2SO. #CancerResearch

👩⚕️ “𝗖𝗹𝗼𝘀𝗲 𝘁𝗵𝗲 𝗖𝗮𝗿𝗲 𝗚𝗮𝗽: 𝗘𝘃𝗲𝗿𝘆𝗼𝗻𝗲 𝗗𝗲𝘀𝗲𝗿𝘃𝗲𝘀 𝗔𝗰𝗰𝗲𝘀𝘀 𝘁𝗼 𝗖𝗮𝗻𝗰𝗲𝗿 𝗖𝗮𝗿𝗲” 🙏 Lung cancer is the most common cancer and the leading cause of cancer death across the world, killing around 1.6 million people every year.   To align with this year’s theme for 𝗪𝗼𝗿𝗹𝗱 𝗟𝘂𝗻𝗴 𝗖𝗮𝗻𝗰𝗲𝗿 𝗗𝗮𝘆, I explored which countries have the highest and lowest access to clinical trials for lung cancer. This clinical trial intelligence has been brought to you by 𝗧𝗔 𝗦𝗰𝗮𝗻, Anju Software’s clinical intelligence solution. 📊 #LungCancer #WLCD #WLCD24 #LivingWithLungCancer #ClinicalResearch #ClinicalTrials #DataScience #TAScan ##ClinicalOperations #DrugDevelopment

#VCBeat #VB100 #VBEF #MedicalNews #MicroInno 💥 The eponymous product of Micro Inno - "Micro Inno Mirror" is an innovative product developed for early screening scenarios of cervical cancer. Based on the rigid scenario of "two cancer screening", it simplifies the original diagnostic process and solves the problems of traditional colposcopy products that can only be carried out in the colposcopy room, inconvenient operation, and unclear vision. 🧪More medical consultations & news follow us!